Lymphoma
Conditions
Keywords
stage III grade 1 follicular lymphoma, stage III grade 2 follicular lymphoma, stage III grade 3 follicular lymphoma, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage IV grade 3 follicular lymphoma
Brief summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment. PURPOSE: This laboratory study is looking at biomarkers in patients with stage III or stage IV follicular lymphoma treated on clinical trial E-1496.
Detailed description
OBJECTIVES: * Correlate gene expression profiles with progression-free survival (PFS) of patients with stage III or IV follicular lymphoma treated with cyclophosphamide, vincristine, and prednisone with or without rituximab on clinical trial E-1496. * Determine if immunoglobulin Fc-gamma receptor polymorphisms are predictive of PFS in these patients. * Assess the significance of the microenvironment by constructing tissue microarrays of follicular lymphoma and immunostaining with relevant biomarkers. * Correlate relevant biomarkers with clinical features, response, and PFS. OUTLINE: This is a multicenter study. Tissue samples are analyzed by gene expression profiling, microarrays to predict gene expression, immunohistochemistry, and immunoglobulin Fc-gamma receptor polymorphism analysis for biological markers. PROJECTED ACCRUAL: A total of 175 samples will be accrued for this study.
Interventions
GENETICgene expression analysis
GENETICmicroarray analysis
GENETICpolymorphism analysis
OTHERdiagnostic laboratory biomarker analysis
OTHERimmunohistochemistry staining method
OTHERimmunologic technique
Sponsors
National Cancer Institute (NCI)
ECOG-ACRIN Cancer Research Group
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of follicular lymphoma * Stage III or IV disease * Received cyclophosphamide, vincristine, and prednisone with or without rituximab on clinical trial E-1496 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation of gene expression profiles with progression-free survival (PFS) | 1 month |
| Prediction of PFS by immunoglobulin Fc-gamma receptor polymorphisms as assessed by immunohistochemistry | 1 month |
| Assessment of significance of microenvironment by constructing tissue microarrays and immunostaining with relevant biomarkers | 1 month |
| Correlation of relevant biomarkers with clinical features, response, and PFS | 1 month |
Outcome results
None listed